Third Quarter 2026
Filed Nov 4, 2026Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Total revenue increased 27%, molecular profiling services revenue increased 27%, and clinical cases increased approximately 21%, but gross margin declined to 66% from 68%, operating expenses increased 42%, net income declined, and quarterly operating cash flow and free cash flow were negative.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenue, three months ended September 30GAAP | $275.4M | – | 27% |
| Molecular profiling services revenue, three months ended September 30GAAP | $262.7M | – | 27% |
| Pharma research and development services revenue, three months ended September 30GAAP | $12.65M | – | – |
| Gross profit, three months ended September 30GAAP | $182.3M | – | – |
| Gross margin, three months ended September 30GAAP | 66% | – | – |
| Cost of services - Molecular profiling services, three months ended September 30GAAP | $89.17M | – | – |
| Cost of services - Pharma research and development services, three months ended September 30GAAP | $3.90M | – | – |
| Operating expenses, three months ended September 30GAAP | $163M | – | 42% |
| Selling and marketing expense, three months ended September 30GAAP | $59.85M | – | – |
| General and administrative expense, three months ended September 30GAAP | $69.28M | – | – |
| Research and development expense, three months ended September 30GAAP | $33.84M | – | – |
| Income from operations, three months ended September 30GAAP | $19.32M | – | – |
| Net income, three months ended September 30GAAP | $15.3M | – | – |
| Net income per share attributable to common shareholders, basic, three months ended September 30GAAP | $0.05 | – | – |
| Net income per share attributable to common shareholders, diluted, three months ended September 30GAAP | $0.05 | – | – |
| Adjusted EBITDA, three months ended September 30non-GAAP | $44.4M | – | – |
| Free cash flow, three months ended September 30non-GAAP | −$39.7M | – | – |
| Total revenue, nine months ended September 30GAAP | $755.2M | – | – |
| Molecular profiling services revenue, nine months ended September 30GAAP | $725.8M | – | – |
| Pharma research and development services revenue, nine months ended September 30GAAP | $29.48M | – | – |
| Income from operations, nine months ended September 30GAAP | $51.52M | – | – |
| Net income (loss), nine months ended September 30GAAP | $14.10M | – | – |
| Net income (loss) per share attributable to common shareholders, basic, nine months ended September 30GAAP | $0.05 | – | – |
| Net income (loss) per share attributable to common shareholders, diluted, nine months ended September 30GAAP | $0.05 | – | – |
| Adjusted EBITDA, nine months ended September 30non-GAAP | $126.3M | – | – |
| Net cash provided by operating activities, nine months ended September 30GAAP | $39.11M | – | – |
| Free cash flow, nine months ended September 30non-GAAP | −$10.78M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Molecular profiling services, three months ended September 30, 2026The increase was primarily driven by an increase in total clinical case volume and ASP improvements. | $262.7M | – | 27% |
| Pharma research and development services, three months ended September 30, 2026Not stated. | $12.65M | – | – |
Full year 2026 outlook
- Revenue$1.04 to $1.05 billion
- NoteGrowth of 28% to 29% compared to full year 2025.
- NoteClinical therapy selection volume growth of approximately 20% compared to full year 2025.
Capital returns
- Share repurchase program of up to $100.0 million.
- Approximately $72.1 million remains available for repurchase under the existing Board authorization.
- Repurchase of common stock of $31,371 thousand for the nine months ended September 30, 2026.
What drove it
- Approximately 61,500 clinical cases, an increase of approximately 21% over the corresponding prior year period.
- Over 358,000 total oncology tests.
- Molecular profiling services revenue growth was primarily driven by higher total clinical case volume and ASP improvements.
- Caris launched Caris Assure Therapy Response Monitoring and enhanced Caris Assure for Therapy selection.
- Caris Confirm, a Whole Genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end.
Concerns
- Gross margin was 66%, compared to 68% in the corresponding prior-year period.
- Operating expenses increased 42%, primarily due to headcount-related costs, increased research and development investment, and marketing expenditures.
- Net income was $15.3 million, compared to $24.3 million in the corresponding prior-year period.
- Net cash used in operating activities was $22.2 million, compared to net cash provided by operating activities of $62.4 million in the corresponding prior-year period.
- The operating cash flow decrease was driven by commercial expansion and marketing expenditures, inventory build-up for new solution launches, and research and development efforts.
- Free cash flow was $(39.7) million.
What to watch
- Execution against full-year 2026 revenue guidance of $1.04 to $1.05 billion.
- Clinical therapy selection volume growth of approximately 20% compared to full year 2025.
- The planned launch of Caris Confirm before year-end.
- Whether case-volume growth and ASP improvements continue to support molecular profiling services revenue.
- Gross-margin performance, operating-expense growth, and cash usage associated with commercial expansion, marketing, inventory, and research and development.
Balance sheet and cash flow
- Cash, cash equivalents, and restricted cash: $665,321 thousand as of September 30, 2026, compared to $797,799 thousand as of December 31, 2025.
- Short-term marketable securities: $102,059 thousand as of September 30, 2026, compared to $2,295 thousand as of December 31, 2025.
- Long-term indebtedness, net: $393,178 thousand as of September 30, 2026, compared to $378,823 thousand as of December 31, 2025.
- Total liabilities: $616,142 thousand as of September 30, 2026, compared to $548,356 thousand as of December 31, 2025.
- Accounts receivable: $133,322 thousand as of September 30, 2026, compared to $112,140 thousand as of December 31, 2025.
- Supplies: $138,372 thousand as of September 30, 2026, compared to $63,625 thousand as of December 31, 2025.
- Capitalized software and purchases of property and equipment: $49,887 thousand for the nine months ended September 30, 2026, compared to $11,170 thousand for the nine months ended September 30, 2025.
- Net cash used in investing activities: $(150,004) thousand for the nine months ended September 30, 2026, compared to $(11,170) thousand for the nine months ended September 30, 2025.
- Net cash used in financing activities: $(21,845) thousand for the nine months ended September 30, 2026, compared to net cash provided by financing activities of $661,590 thousand for the nine months ended September 30, 2025.
Analysis
Caris reported third-quarter revenue of $275.4 million, up 27% from $216.8 million. Molecular profiling services generated $262.7 million, also up 27%, and management attributed the increase to higher clinical case volume and ASP improvements. The company completed approximately 61,500 clinical cases, up approximately 21%, and reported over 358,000 total oncology tests. Molecular profiling remained the principal source of revenue, while pharma research and development services revenue was $12,651 thousand.
Gross profit was $182.3 million and gross margin was 66%, versus $147.5 million and 68% in the corresponding prior-year period. The two-point gross-margin decline occurred alongside revenue growth. Operating expenses rose 42% to $163.0 million, with the company citing headcount-related costs, higher research and development investment, and marketing expenditures. Income from operations was $19,316 thousand, compared with $32,642 thousand in the prior-year quarter.
Net income was $15.3 million, compared with $24.3 million, and basic and diluted net income per share were each $0.05, compared with $0.09 and $0.08, respectively. Adjusted EBITDA was positive at $44.4 million, but below $51.2 million in the corresponding prior-year period. For the first nine months, total revenue was $755,243 thousand, income from operations was $51,524 thousand, net income was $14,103 thousand, and Adjusted EBITDA was $126,322 thousand.
Cash conversion weakened in the quarter. Net cash used in operating activities was $22.2 million, compared with net cash provided by operating activities of $62.4 million in the prior-year quarter, while free cash flow was $(39.7) million compared with $55.3 million. Management attributed the operating-cash-flow decrease to commercial expansion and marketing, inventory build-up for new launches, and research and development. For the nine months, operating cash flow remained positive at $39,107 thousand, but free cash flow was $(10,780) thousand following $49,887 thousand of capitalized software and property and equipment purchases.
Caris increased its full-year 2026 revenue outlook to $1.04 to $1.05 billion, representing growth of 28% to 29%, and reaffirmed expected clinical therapy selection volume growth of approximately 20%. The balance sheet reported $665,321 thousand of cash, cash equivalents, and restricted cash, $102,059 thousand of short-term marketable securities, and $393,178 thousand of long-term indebtedness, net. The company also had approximately $72.1 million remaining under its $100.0 million share repurchase authorization.
Management, verbatim
This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year.
David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences
Caris Assure® is now available for therapeutic response monitoring, and Caris Confirm, our Whole Genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end.
David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences
Not in the filing
stated, not guessed- Previous-release outlook was not provided, so no comparison of actual results with prior guidance is available.
- Prior-quarter revenue, margins, earnings, cash flow, and segment comparisons were not reported.
- Forward guidance for gross margin, operating expenses, tax rate, earnings, Adjusted EBITDA, operating cash flow, free cash flow, capital expenditures, cash, debt, or repurchases was not reported.
- A quarterly dividend was not reported.
- A specific driver for pharma research and development services revenue was not reported.
- Year-over-year percentage changes for gross profit, gross margin, individual operating-expense categories, operating income, net income, EPS, Adjusted EBITDA, and nine-month results were not reported on their respective rows.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.